Pacific Biosciences of California Company Profile (NASDAQ:PACB)

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California, Inc. (NASDAQ:PACB) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm earned $20.07 million during the quarter, compared to analyst estimates of $23.34 million. Pacific Biosciences of California had a negative net margin of 89.67% and a negative return on equity of 93.31%. The business's revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) earnings per share. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Pacific Biosciences of California.

2 brokerages have issued 1 year price objectives for Pacific Biosciences of California's stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $10.00 in the next year. View Analyst Ratings for Pacific Biosciences of California.

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:

• 1. According to Zacks Investment Research, "In the past six months, shares of Pacific Biosciences underperformed the broader industry in terms of price. The company posted an unimpressive second quarter of fiscal 2017, registering wider-than-expected loss. Of the other concerns, the DNA sequencing market is highly competitive owing to the presence of several established players. Cutthroat competition in the niche space is a headwind in our view. On the brighter side, solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. However, headwinds related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system and higher non-cash operating expenses are expected to mar prospects over the long haul. Meanwhile, the company witnessed significant strength in China. Notably, it has placed numerous system orders in the region with both new and existing customers." (8/10/2017)
• 2. Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)

Some companies that are related to Pacific Biosciences of California include Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Neovasc (NVCN), IRIDEX Corporation (IRIX), Harvard Bioscience (HBIO), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Fulgent Genetic (FLGT) and Presbia PLC (LENS).

Pacific Biosciences of California's management team includes the folowing people:

• Michael W. Hunkapiller Ph.D., Chairman of the Board, President, Chief Executive Officer
• Susan K. Barnes, Chief Financial Officer, Executive Vice President, Principal Accounting Officer
• Kevin P. Corcoran, Senior Vice President - Market Development
• Michael Phillips, Senior Vice President - Research and Development
• William W. Ericson, Lead Independent Director
• David Botstein Ph.D., Independent Director
• Brook H. Byers Ph.D., Independent Director
• Randall Livingston, Independent Director
• John F. Milligan Ph.D., Independent Director

Pacific Biosciences of California's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (9.17%), Capital World Investors (6.78%), Vanguard Group Inc. (4.04%), State Street Corp (1.32%), Frontier Capital Management Co. LLC (1.61%) and Kennedy Capital Management Inc. (1.27%). View Institutional Ownership Trends for Pacific Biosciences of California.

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Lord Abbett & CO. LLC, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Ameriprise Financial Inc., Citadel Advisors LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Pacific Biosciences of California's stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Maverick Capital Ltd., Frontier Capital Management Co. LLC, Kennedy Capital Management Inc., Spark Investment Management LLC, Vanguard Group Inc., California Public Employees Retirement System and Trellus Management Company LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Pacific Biosciences of California stock can currently be purchased for approximately $5.39.